<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cheng LP</submitter><funding>Collaborative Innovation Fund</funding><funding>Shanghai Municipal Education Commission</funding><pagination>1205-1218</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11244698</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(12)</volume><pubmed_abstract>&lt;b>Aim:&lt;/b> The purpose of this study is to design and synthesize a new series of sulfamethazine derivatives as potent neuraminidase inhibitors. &lt;b>Materials &amp; methods:&lt;/b> A sulfamethazine lead compound, &lt;b>ZINC670537&lt;/b>, was first identified by structure-based virtual screening technique, then some novel inhibitors &lt;b>X1-X10&lt;/b> based on &lt;b>ZINC670537&lt;/b> were designed and synthesized. &lt;b>Results:&lt;/b> Compound &lt;b>X3&lt;/b> exerts the most good potency in inhibiting the wild-type H5N1 NA (IC&lt;sub>50&lt;/sub> = 6.74 μM) and the H274Y mutant NA (IC&lt;sub>50&lt;/sub> = 21.09 μM). 150-cavity occupation is very important in determining activities of these inhibitors. The sulfamethazine moiety also plays an important role. &lt;b>Conclusion:&lt;/b> Compound &lt;b>X3&lt;/b> maybe regard as a good anti-influenza candidate to preform further study.</pubmed_abstract><journal>Future medicinal chemistry</journal><pubmed_title>Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors.</pubmed_title><pmcid>PMC11244698</pmcid><funding_grant_id>XTCX2023</funding_grant_id><pubmed_authors>Zhang XY</pubmed_authors><pubmed_authors>Cheng LP</pubmed_authors><pubmed_authors>Xiao XZ</pubmed_authors><pubmed_authors>Pang W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors.</name><description>&lt;b>Aim:&lt;/b> The purpose of this study is to design and synthesize a new series of sulfamethazine derivatives as potent neuraminidase inhibitors. &lt;b>Materials &amp; methods:&lt;/b> A sulfamethazine lead compound, &lt;b>ZINC670537&lt;/b>, was first identified by structure-based virtual screening technique, then some novel inhibitors &lt;b>X1-X10&lt;/b> based on &lt;b>ZINC670537&lt;/b> were designed and synthesized. &lt;b>Results:&lt;/b> Compound &lt;b>X3&lt;/b> exerts the most good potency in inhibiting the wild-type H5N1 NA (IC&lt;sub>50&lt;/sub> = 6.74 μM) and the H274Y mutant NA (IC&lt;sub>50&lt;/sub> = 21.09 μM). 150-cavity occupation is very important in determining activities of these inhibitors. The sulfamethazine moiety also plays an important role. &lt;b>Conclusion:&lt;/b> Compound &lt;b>X3&lt;/b> maybe regard as a good anti-influenza candidate to preform further study.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-01T18:03:57.166Z</modification><creation>2026-05-19T03:07:02.661Z</creation></dates><accession>S-EPMC11244698</accession><cross_references><pubmed>38989986</pubmed><doi>10.1080/17568919.2024.2342688</doi></cross_references></HashMap>